Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVaxID: RSV vaccine strategies in lung and allogeneic HSCT recipients
2025-524374-42-00Phase 2Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- Jul 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of RSVpreF vaccine and GSK3003899A in respiratory syncytial virus disease (RSV) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: RSV antibody seroresponse rate at 1 month after vaccination. Planned start Jul 2026; status: authorised.
02
Drugs
RSVpreF vaccineGSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2025-524374-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524374-42-00.